Journal Mobile Options
Table of Contents
Vol. 66, No. 3, 2008
Issue release date: October 2008
Gynecol Obstet Invest 2008;66:178–183

Gestational Diabetes: Using a Portable Glucometer to Simplify the Approach to Screening

Agarwal M.M. · Dhatt S. · Safraou M.-F.
aDepartment of Pathology, Faculty of Medicine, UAE University, and bDepartment of Pathology, Tawam Hospital, Al Ain, United Arab Emirates; cDepartment of Endocrinology, Hopital Europeen Georges Pompidou, Paris, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: In populations at a high-risk for gestational diabetes (GDM), the recommendation of screening every pregnant woman with the oral glucose tolerance test (OGTT) is very demanding. Aim: To assess the usefulness of the portable, plasma optimized glucometer in simplifying the approach to screening of GDM. Methods: 1,662 pregnant women underwent the one-step 75 g OGTT for routine screening of GDM, as defined by the criteria of the American Diabetes Association. The glucometer was used to measure the initial fasting venous whole blood glucose (FBG) to assess its value as a screening test in predicting the need to proceed with the OGTT. Results: 186 (11.2%) women had GDM. The area under the receiver operating characteristic curve (AUC) of the FBG was 0.876 (95% CI 0.847–0.906). A FBG threshold (at an acceptable sensitivity of 85%) independently could ‘rule-out’ GDM in 1,138 (68.5%) women; i.e. over two-thirds of the women would not need to continue with the cumbersome OGTT. Conclusions: Using the glucometer to initially measure the venous FBG as a screen can help to significantly reduce the number of OGTTs needed for the diagnosis of GDM. This algorithm offers a simple, practical, cost-effective and patient-friendly approach for the screening of GDM.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Gestational Diabetes Mellitus: Position statement American Diabetes Association. Diabetes Care 2004;27(suppl 1):S88–S90.

    External Resources

  2. Agarwal MM, Dhatt GS, Punnose J, Koster G: Gestational diabetes: dilemma caused by multiple international diagnostic criteria. Diabet Med 2005;22:1731–1736.
  3. International Diabetes Federation: Diabetes e-Atlas, ed 2. Brussels, 2003. Available at:
  4. Hughes PF, Agarwal M, Newman P, Morrison J: Screening for gestational diabetes in a multi-ethnic population. Diab Res Clin Prac 1995;28:73–78.
  5. Yue DK, Molyneaux LM, Ross GP, Constantino MI, Child AG, Turtle JR: Why does ethnicity affect prevalence of gestational diabetes? The underwater volcano theory. Diabet Med 1996;13:748–752.
  6. Agarwal MM, Hughes PF, Punnose J, Ezimokhai M: Fasting plasma glucose as a screening test for gestational diabetes in a multi-ethnic, high-risk population. Diabet Med 2000;17:720–726.
  7. Agarwal MM, Dhatt GS, Punnose J, Koster G: Gestational Diabetes: a reappraisal of HBA1c as a screening test. Acta Obstet Gynecol Scand 2005;84:1159–1163.
  8. Agarwal MM, Hughes PF, Punnose J, Ezimokhai M, Thomas L: Gestational diabetes screening of a multiethnic, high-risk population using glycated proteins. Diab Res Clin Prac 2001;51:67–73.
  9. Hughes PF, Agarwal M, Newman P, Morrison J: An evaluation of fructosamine estimation in screening for gestational diabetes mellitus. Diabet Med 1995;12:708–712.
  10. Agarwal MM, Hughes PF, Ezimokhai M: Screening for gestational diabetes in a high risk population using fasting plasma glucose. Int J Gynecol Obstet 2000;68:147–148.
  11. Agarwal MM, Dhatt GS, Punnose J, Koster G: Gestational Diabetes in a high-risk population: using the fasting plasma glucose to simplify the diagnostic algorithm. Eur J Obstet Gynecol Reprod Biol 2005;120:39–44.
  12. Agarwal MM, Dhatt GS, Punnose J: Gestational diabetes: utility of fasting plasma glucose as a screening test depends upon the diagnostic criteria. Diabet Med 2006;23:1319–1326.
  13. Flahault A, Cadilhac M, Thomas G: Sample size calculation should be performed for design accuracy in diagnostic test studies. J Clin Epidemiol 2005;58:859–862.
  14. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436–472.
  15. Hanna FWF, Peters JR: Screening for gestational diabetes; past, present and future. Diabet Med 2002;19:351–358.
  16. Agarwal MM, Dhatt GS: Fasting plasma glucose as a screening test for gestational diabetes mellitus. Arch Gynecol Obstet 2007;275:81–87.
  17. Carr SR: Screening for gestational diabetes mellitus: a perspective in 1998. Diabetes Care 1998;21(suppl 2):B14–B18.

    External Resources

  18. D’Orazio P, Burnett WR, Fogh-Andersen N, Jacobs E, Kuwa K, Külpmann WR, et al: The International Federation of Clinical Chemistry Scientific Division Working Group on Selective Electrodes and Point of Care Testing: Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem 2005:51:1573–1576.
  19. Tuomilehto J: Point: a glucose tolerance test is important for clinical practice. Diabetes Care 2002;25:1880–1882.
  20. Davidson MB: Counterpoint: the oral glucose tolerance test is superfluous. Diabetes Care 2002;25:1883–1885.
  21. Agarwal MM, Dhatt GS, Bali N: Fasting capillary glucose as a screening test for gestational diabetes mellitus. BJOG 2007;114:237–238.
  22. Metzger BE: Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Highlights. 67th Annual Scientific Sessions of the American Diabetes Association, Chicago, 2007.
  23. Mello G, Elena P, Ognibene A, Cioni R, Tondi F, Pezzati P, Pratesi M, Scarselli G, Messeri G: Lack of concordance between the 75 and 100 g glucose load tests for the diagnosis of gestational diabetes mellitus. Clin Chem 2006;52:1679–1684.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50